Endogenous GLP-1 is an incretin hormone that modulates pancreatic insulin secretion, insulin secretion, and peripheral insulin sensitivity and delays gastric emptying.319 In the small LEAN phase IIa trial, NASH resolution was achieved by 39% of nondiabetic NASH patients treated for a year with liraglutide, a once-daily GLP-1RA, compared to 9% of patients treated with placebo (p = 0.02).320 Recently, semaglutide, another GLP-1RA, was reported to lead to NASH resolution in 59% of subjects, although the results have not yet been published in a peer-reviewed manuscript. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.